Background Infants born at 33–35 completed weeks' gestational age (wGA) aged< 6 months
at the start of or born during respiratory syncytial virus (RSV) season and classified as …

Background: Respiratory syncytial virus (RSV) infection frequently results in RSV-related
hospitalization (RSVH) in young infants. We examined the outcomes of palivizumab …

Background. Respiratory syncytial virus (RSV) is a major cause of hospitalization in preterm
infants and infants with chronic lung disease (CLD). Palivizumab, a humanized monoclonal …

Background. Palivizumab is FDA-approved for prevention of serious RSV lower respiratory
tract infection (LRTI) in children at high-risk of RSV disease. On July 2014, the American …

Background. Respiratory syncytial virus (RSV) represents a significant public health burden
and the leading cause of lower respiratory tract infections globally, and it is the major cause …

Abstract In Quebec, Canada, eligibility for palivizumab (PVZ) immunoprophylaxis was
expanded in fall 2016 to include healthy-full-term (HFT) infants residing in the circumpolar …

Background Infection with respiratory syncytial virus (RSV) is common among young
children insured through Medicaid in the United States. Complete and timely dosing with …

We examined the dosing regimens, compliance, and outcomes of premature infants who
received palivizumab within the Canadian Registry of Palivizumab (CARESS). Infants …

Background Immunoprophylaxis with palivizumab can reduce respiratory syncytial virus
(RSV) infections and hospitalizations. Criteria in British Columbia limit the use of …

Background: Immunocompromised children are at increased risk for respiratory syncytial
virus (RSV) infection with associated morbidity and mortality. Prophylaxis is usually provided …